The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTNEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Same-day shipping now live from the US West Coast · order by 2:30 PM PT weekdays, 12:00 PM PT Saturday →NEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
CBL-514 β€’ Research evidence

CBL-514 Sample Size: Power, Precision and Rare Events

Quick answerA trial's sample size is planned around particular assumptions and outcomes. Enough participants to detect an efficacy signal does not mean enough to estimate every subgroup effect or rule out uncommon harms.

Published November 14, 2026 Β· Disguised Alpha Β· Source-linked research guide

Research education only. These notes do not provide instructions for human use or establish that a supplier’s material is equivalent to a clinical study formulation.

A participant count needs a purpose

The 2025 CBL-514 publication reports 76 randomized participants.[1] That count alone does not describe the strength of every possible inference. A sample-size calculation concerns a selected endpoint, assumed effect, variability and statistical design.

FDA’s E9 guidance treats sample-size planning as part of trial design.[2] When reading a CBL-514 report, locate the calculation and compare its assumptions with the actual enrollment and available outcomes. Do not calculate a new β€œobserved power” percentage from the result and treat it as a replacement for uncertainty estimates.

An original rare-event example

Hypothetical, not CBL-514 safety data: if an event independently affects 1% of exposed people, the probability of observing no events in 50 people is 0.99 raised to the 50th power, approximately 61%. Zero observed events in such a group would therefore be quite compatible with a 1% underlying event probability.

The example assumes independent observations, equal risk and complete observation. Real safety studies may not satisfy those assumptions. Its purpose is narrower: to show why β€œnone observed” is not the same as β€œcannot occur.”

Follow-up also matters. Fifty people observed for a week and fifty observed for a year offer different opportunities to detect delayed events, even though the headline participant count matches.

What larger studies can and cannot fix

More informative observations generally improve precision, but additional participants do not automatically repair a biased measurement procedure, an unsuitable comparator or selective reporting. The quality of data and the relevance of the question remain essential.

For subgroup claims, record how many people actually contributed to that subgroup. A total enrollment figure can conceal very small cells after participants are divided by baseline severity, age or other characteristics.

Our suggested evidence note includes the planned size, actual randomized size, endpoint-specific count, follow-up duration and stated purpose of the calculation. That record supports a more useful conclusion than calling a CBL-514 trial simply β€œlarge” or β€œsmall.”

Frequently asked questions

Does statistical significance show that a study was large enough for safety?

No. An efficacy test and the ability to detect uncommon or delayed harms are different questions.

Can I infer a subgroup result from the total sample size?

No. You need the subgroup's own participant count, analysis and uncertainty.

Continue your CBL-514 research

Compare the original study evidence with the documentation for the specific material you are reviewing.

Sources and further reading

  1. Gold et al., 2025 CBL-514 trial
  2. FDA: E9 statistical principles, sample-size planning

Publisher disclosure: Disguised Alpha is a research-material supplier. This guide is an educational interpretation of the linked sources, not an independent clinical review or a statement of regulatory approval.

References describe the studies or methods identified in the text. They do not independently certify the composition, clinical suitability or performance of Disguised Alpha products.

βœ“
Loading...
25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop